IMAGE IN CARDIOLOGY

DOI: 10.4244/EIJV10I8A169

Failing transcatheter aortic valve treated by transcatheter aortic valve in transcatheter aortic valve (TAV-in-TAV) implantation: valve safety versus valve durability

Beatriz Vaquerizo, MD, PhD; Giuseppe Martucci, MD; Jean Buithieu, MD; Benoit de Varennes, MD; Kevin Lachappelle, MD; Nicolo Piazza*, MD, PhD

We present the case of a 67-year-old male who presented with a degenerated 29 mm CoreValve (Medtronic, Minneapolis, MN, USA) five years after its successful implantation for severe bicuspid aortic valve stenosis (Online Figure 1). During the most recent hospitalisation, for an acute coronary syndrome, transoesophageal echocardiography (TEE) detected a new-onset severe transvalvular AR due to a prolapsing bioprosthetic valve leaflet (Figure 1A, Figure 1B, Figure 1F, Moving image 1). Signs and symptoms suggestive of endocarditis were absent. The Heart Team decided to proceed with a transcatheter aortic valve in transcatheter aortic valve (TAV-in-TAV) implantation using a 29 mm CoreValve prosthesis (Figure 1C). Contrast aortography and TEE confirmed no transvalvular regurgitation and residual mild paravalvular AR (Figure 1D, Moving image 2) with a transvalvular gradient <10 mmHg. The haemodynamic AR index increased significantly from 10.2 to 42.0 (Figure 1C, Figure 1E). After the procedure, the patient improved progressively and was discharged four days later with New York Heart Association functional Class I-II.

Figure 1. Late structural transcatheter aortic valve degeneration after transcatheter aortic valve replacement. Severe aortic regurgitation (AR) due to prolapse of one cusp of the CoreValve by TEE (A&B). After TAV-in-TAV, TEE confirmed competent leaflet coaptation of the new prosthesis without significant AR (D&F), and the haemodynamic AR ([Aodia–LVEDP]/Aosyst ×100) increased significantly from 10.2 ([40-24/158]×100) to 42.0 ([79-13/157]×100) (C&E).

Little is known about the long-term durability and outcomes of transcatheter aortic valves. Undoubtedly, valve durability emerges as the most persistent criticism of transcatheter aortic valve replacement (TAVR). To the best of our knowledge, there has been only one other case report of late structural valve degeneration of a transcatheter valve after TAVR. It seems that, similar to most surgical bioprosthetic tissue valves, such valves deteriorate with time, meaning that there is adequate warning and time for a planned second procedure (e.g., TAV-in-TAV). Thus, valve durability, although critical, is not necessarily the key factor in keeping patients alive.

Conflict of interest statement

N. Piazza is a proctor for and has received speaker’s fees from Medtronic Inc. The other authors have no conflicts of interest to declare.

Online data supplement

Moving image 1. Severe aortic regurgitation (AR) presentation due to prolapse of one cusp of the transcatheter heart valve (THV) (A&B).

Moving image 2. Transoesophageal echocardiography (TEE) confirmed competent aortic valve leaflet coaptation without transvalvular regurgitation and residual mild paravalvular AR.

Online Figure 1. Native calcified bicuspid aortic valve by transoesophageal echocardiography (TEE).

Supplementary data

To read the full content of this article, please download the PDF.

Moving image 1a. Severe aortic regurgitation (AR) presentation due to prolapse of one cusp of the transcatheter heart valve (THV).

Moving image 1b. Severe aortic regurgitation (AR) presentation due to prolapse of one cusp of the transcatheter heart valve (THV).

Moving image 2. Transoesophageal echocardiography (TEE) confirmed competent aortic valve leaflet coaptation without transvalvular regurgitation and residual mild paravalvular AR.

Volume 10 Number 8
Dec 22, 2014
Volume 10 Number 8
View full issue


Key metrics

Suggested by Cory

State-of-the-Art

10.4244/EIJ-D-23-01050 Jul 15, 2024
Durability of transcatheter aortic valve implantation
Ternacle J et al
free

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA8 Sep 18, 2016
Late degeneration of transcatheter aortic valves: pathogenesis and management
Barbanti M and Tamburino C
free

10.4244/EIJV15I10A160 Nov 15, 2019
Durability of transcatheter bioprosthetic aortic valves: the story so far
Capodanno D et al
free

10.4244/EIJV11SWA34 Sep 17, 2015
Durability of devices: long-term results and clinical outcomes
Arsalan M and Mack MJ
free

10.4244/EIJV14I15A263 Feb 7, 2019
Valve durability – is this the Achilles’ heel of TAVI?
Jabbour R and Mikhail G
free

CLINICAL RESEARCH

10.4244/EIJY15M10_10 Oct 10, 2016
Four-year experience with the CoreValve transcatheter heart valve
Kovac J et al
free

CLINICAL RESEARCH

10.4244/EIJ-D-18-00779 Mar 20, 2019
Long-term results and durability of the CoreValve transcatheter aortic bioprosthesis: outcomes beyond five years
Panico R et al
free
Trending articles
153.65

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.25

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved